Previous 10 |
CymaBay Therapeutics, Inc. (CBAY) Q3 2018 Earnings Conference Call November 6, 2018 4:30 PM ET Executives Dan Menold – Vice President-Finance Sujal Shah – Chief Executive Officer Pol Boudes – Chief Medical Officer Chuck McWherter – Chief Scientific O...
Conference call and webcast today at 4:30p.m. ET NEWARK, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY) a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announ...
NEWARK, Calif., Oct. 30, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live aud...
CymaBay Therapeutics ( CBAY +2.1% ) initiates a Phase 3 clinical trial, ENHANCE , evaluating seladelpar in patients with primary biliary cholangitis (PBC) who have not responded adequately to or are intolerant of standard first-line ursodeoxycholic acid. More news on: CymaBay Therap...
Phase 3 patient enrollment commenced with multiple investigational sites in the U.S. initiated Team expanded with key hires focused on delivering a high-quality registration package NEWARK, Calif., Oct. 30, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), today a...
News, Short Squeeze, Breakout and More Instantly...
CymaBay Therapeutics Inc. Company Name:
CBAY Stock Symbol:
NASDAQ Market:
CymaBay Therapeutics Inc. Website:
Acquisition Reinforces Gilead’s Leadership in Developing Innovative Therapies For Challenging Liver Diseases Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for appr...
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is the focus of IBN's latest stock spotlight. The company's shares have moved 0.06% on the day to $32.49. CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chr...
2024-03-12 10:45:01 ET UiPath Inc (PATH) PATH is trading UP for the last 5 days, and it at trading at $24.64 with volume of 4,269,666 and a one day change of $0.54 (2.25%). UiPath Inc has a 52-week low of 12.38 and a 52-week high of $27.87. The business's 50-day moving average price...